Literature DB >> 17174525

Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine.

Zhi-Ye Zhuang1, Yasuhiko Kawasaki, Ping-Heng Tan, Yeong-Ray Wen, Jing Huang, Ru-Rong Ji.   

Abstract

Accumulating evidence suggests that microglial cells in the spinal cord play an important role in the development of neuropathic pain. However, it remains largely unknown how glia interact with neurons in the spinal cord after peripheral nerve injury. Recent studies suggest that the chemokine fractalkine may mediate neural/microglial interaction via its sole receptor CX3CR1. We have examined how fractalkine activates microglia in a neuropathic pain condition produced by spinal nerve ligation (SNL). SNL induced an upregulation of CX3CR1 in spinal microglia that began on day 1, peaked on day 3, and maintained on day 10. Intrathecal injection of a neutralizing antibody against CX3CR1 suppressed not only mechanical allodynia but also the activation of p38 MAPK in spinal microglia following SNL. Conversely, intrathecal infusion of fractalkine produced a marked p38 activation and mechanical allodynia. SNL also induced a dramatic reduction of the membrane-bound fractalkine in the dorsal root ganglion, suggesting a cleavage and release of this chemokine after nerve injury. Finally, application of fractalkine to spinal slices did not produce acute facilitation of excitatory synaptic transmission in lamina II dorsal horn neurons, arguing against a direct action of fractalkine on spinal neurons. Collectively, our data suggest that (a) fractalkine cleavage (release) after nerve injury may play an important role in neural-glial interaction, and (b) microglial CX3CR1/p38 MAPK pathway is critical for the development of neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17174525      PMCID: PMC2084372          DOI: 10.1016/j.bbi.2006.11.003

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  48 in total

1.  Activated microglia contribute to the maintenance of chronic pain after spinal cord injury.

Authors:  Bryan C Hains; Stephen G Waxman
Journal:  J Neurosci       Date:  2006-04-19       Impact factor: 6.167

2.  Systemic and intrathecal effects of a novel series of phospholipase A2 inhibitors on hyperalgesia and spinal prostaglandin E2 release.

Authors:  Tony L Yaksh; George Kokotos; Camilla I Svensson; Daren Stephens; Christoforos G Kokotos; Bethany Fitzsimmons; Dimitra Hadjipavlou-Litina; Xiao-Ying Hua; Edward A Dennis
Journal:  J Pharmacol Exp Ther       Date:  2005-10-03       Impact factor: 4.030

3.  Intrathecal minocycline attenuates peripheral inflammation-induced hyperalgesia by inhibiting p38 MAPK in spinal microglia.

Authors:  Xiao-Ying Hua; Camilla I Svensson; Tomohiro Matsui; Bethany Fitzsimmons; Tony L Yaksh; Michael Webb
Journal:  Eur J Neurosci       Date:  2005-11       Impact factor: 3.386

4.  Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain.

Authors:  Jill A Lindia; Erin McGowan; Nina Jochnowitz; Catherine Abbadie
Journal:  J Pain       Date:  2005-07       Impact factor: 5.820

5.  Peripheral axonal injury results in reduced mu opioid receptor pre- and post-synaptic action in the spinal cord.

Authors:  Tatsuro Kohno; Ru-Rong Ji; Nobuko Ito; Andrew J Allchorne; Katia Befort; Laurie A Karchewski; Clifford J Woolf
Journal:  Pain       Date:  2005-09       Impact factor: 6.961

6.  A peptide c-Jun N-terminal kinase (JNK) inhibitor blocks mechanical allodynia after spinal nerve ligation: respective roles of JNK activation in primary sensory neurons and spinal astrocytes for neuropathic pain development and maintenance.

Authors:  Zhi-Ye Zhuang; Yeong-Ray Wen; De-Ren Zhang; Tiziana Borsello; Christophe Bonny; Gary R Strichartz; Isabelle Decosterd; Ru-Rong Ji
Journal:  J Neurosci       Date:  2006-03-29       Impact factor: 6.167

7.  Activation of p38 mitogen-activated protein kinase in spinal microglia mediates morphine antinociceptive tolerance.

Authors:  Yu Cui; Yu Chen; Jun-Li Zhi; Rui-Xian Guo; Jian-Qiang Feng; Pei-Xi Chen
Journal:  Brain Res       Date:  2006-01-03       Impact factor: 3.252

8.  Different effects of opioid and cannabinoid receptor agonists on C-fiber-induced extracellular signal-regulated kinase activation in dorsal horn neurons in normal and spinal nerve-ligated rats.

Authors:  Yasuhiko Kawasaki; Tatsuro Kohno; Ru-Rong Ji
Journal:  J Pharmacol Exp Ther       Date:  2005-10-12       Impact factor: 4.030

9.  An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat.

Authors:  Sun Ho Kim; Jin Mo Chung
Journal:  Pain       Date:  1992-09       Impact factor: 6.961

10.  Activation of glia and microglial p38 MAPK in medullary dorsal horn contributes to tactile hypersensitivity following trigeminal sensory nerve injury.

Authors:  Zheng Gen Piao; Ik-Hyun Cho; Chul Kyu Park; Jin Pyo Hong; Se-Young Choi; Sung Joong Lee; Seungbok Lee; Kyungpyo Park; Joong Soo Kim; Seog Bae Oh
Journal:  Pain       Date:  2006-02-21       Impact factor: 6.961

View more
  139 in total

1.  Spinal CX3CL1/CX3CR1 May Not Directly Participate in the Development of Morphine Tolerance in Rats.

Authors:  Yawen Peng; Genhua Guo; Bin Shu; Daiqiang Liu; Peng Su; Xuming Zhang; Feng Gao
Journal:  Neurochem Res       Date:  2017-08-03       Impact factor: 3.996

2.  Spinal CCL2 Promotes Central Sensitization, Long-Term Potentiation, and Inflammatory Pain via CCR2: Further Insights into Molecular, Synaptic, and Cellular Mechanisms.

Authors:  Rou-Gang Xie; Yong-Jing Gao; Chul-Kyu Park; Ning Lu; Ceng Luo; Wen-Ting Wang; Sheng-Xi Wu; Ru-Rong Ji
Journal:  Neurosci Bull       Date:  2017-03-06       Impact factor: 5.203

Review 3.  Chemokines, neuronal-glial interactions, and central processing of neuropathic pain.

Authors:  Yong-Jing Gao; Ru-Rong Ji
Journal:  Pharmacol Ther       Date:  2010-02-01       Impact factor: 12.310

4.  A p38 mitogen-activated protein kinase-dependent mechanism of disinhibition in spinal synaptic transmission induced by tumor necrosis factor-alpha.

Authors:  Haijun Zhang; Hui Nei; Patrick M Dougherty
Journal:  J Neurosci       Date:  2010-09-22       Impact factor: 6.167

5.  Spinal inhibition of p38 MAP kinase reduces inflammatory and neuropathic pain in male but not female mice: Sex-dependent microglial signaling in the spinal cord.

Authors:  Sarah Taves; Temugin Berta; Da-Lu Liu; Sophie Gan; Gang Chen; Yong Ho Kim; Thomas Van de Ven; Stefan Laufer; Ru-Rong Ji
Journal:  Brain Behav Immun       Date:  2015-10-19       Impact factor: 7.217

6.  Evidence that spinal astrocytes but not microglia contribute to the pathogenesis of Paclitaxel-induced painful neuropathy.

Authors:  Haijun Zhang; Seo-Yeon Yoon; Hongmei Zhang; Patrick M Dougherty
Journal:  J Pain       Date:  2012-01-29       Impact factor: 5.820

7.  Possible role of spinal astrocytes in maintaining chronic pain sensitization: review of current evidence with focus on bFGF/JNK pathway.

Authors:  Ru-Rong Ji; Yasuhiko Kawasaki; Zhi-Ye Zhuang; Yeong-Ray Wen; Isabelle Decosterd
Journal:  Neuron Glia Biol       Date:  2006-11

8.  Altered expression of glial markers, chemokines, and opioid receptors in the spinal cord of type 2 diabetic monkeys.

Authors:  Norikazu Kiguchi; Huiping Ding; Christopher M Peters; Nancy D Kock; Shiroh Kishioka; J Mark Cline; Janice D Wagner; Mei-Chuan Ko
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2016-10-14       Impact factor: 5.187

9.  P2X4-receptor-mediated synthesis and release of brain-derived neurotrophic factor in microglia is dependent on calcium and p38-mitogen-activated protein kinase activation.

Authors:  Tuan Trang; Simon Beggs; Xiang Wan; Michael W Salter
Journal:  J Neurosci       Date:  2009-03-18       Impact factor: 6.167

Review 10.  Chemokines and pain mechanisms.

Authors:  Catherine Abbadie; Sonia Bhangoo; Yves De Koninck; Marzia Malcangio; Stéphane Melik-Parsadaniantz; Fletcher A White
Journal:  Brain Res Rev       Date:  2008-12-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.